INVEST IN IMETABOLIC BIOPHARMA TODAY!
Our technology-powered iPlatform™ pipeline removes the roadblocks that typically make drug development slow, expensive, and inefficient, with the aim to put lifesaving treatments in the hands of communities everywhere.
Our revolutionary approach to drug development has already landed us three strategic technology and pharma industry partnership deals, five disease therapeutic asset programs already in motion, and four additional programs prepared to go online.
We are led by a passionate and highly talented team who understands the human nature of the work we do. We are determined to apply our collective knowledge and experience to bring hope, empowerment, and opportunity to our investors and their communities.
At iMBP, we are the next stage of biotech evolution. We are combining innovative technology with biotechnology as part of our proprietary, cutting-edge “TechBio” approach to biopharma. We give communities the opportunity to invest in their own health as we improve the way drugs are discovered to make them more effective and affordable. We have strategic partnerships in place and drug candidates in development in our key markets of metabolic, cardiovascular, and neurodegenerative diseases. The company is pre-revenue and in the prototype phase.
iMBP is developing a revolutionary approach to drug discovery to help people live longer, healthier, and happier lives with their loved ones. Our founder, Chairman, and CEO Dr. Urban A. Kiernan, Ph.D. is a seasoned BioTech leader with decades of industry business and scientific research experience. However, his passion is what drives him beyond what any academic or work experience could ever afford him.
"The feeling of helplessness I experienced when my first wife died from cancer was devastating. Then, a single Dad with two little girls, the world turned upside-down. From this pain, I recognized the utopic potential the biopharma industry has to offer... and that is the power to keep families together... for just one more... one more memory to hold onto. You cannot put a price tag on that. This is my passion and this is why I created iMBP."
– Dr. Urban A. Kiernan –
Husband, Father, Founder & CEO of iMBP
The Problem & Our solution
Today’s developmental process for new, lifesaving drugs is complex, expensive, and time-consuming. The current industry solution is to simply spend more money, resulting in over-expensive therapeutics with marginal benefits. Ultimately, the deficiencies of this system places the cost burden on the people who need these therapeutic solutions most.
Our Solution was the development of iPlatform™, our proprietary computational approach that uses in-silico therapeutic discovery and molecular design to improve upon traditional biotechnology. This creates both economic and time-saving advantages to drug discovery, allowing for life-saving solutions to potentially reach the clinic faster and more affordably. This is the value that TechBio offers to you and your loved ones. Enabled through our partner Amazon Web Services (AWS), iPlatform™ is rapidly evolving and already producing drug asset leads for the expansion of the iMBP drug pipeline.
the market & Our Traction
Our drug asset efforts are currently focused in three primary areas: metabolic disease, cardiovascular disease, and neurodegenerative disease (Alzheimer’s Disease).
Our TechBio approach has allowed iMBP to achieve multiple milestones normally not experienced in BioTech companies until much later in life, including:
"Ligand is proud of its heritage of establishing strategic partnerships with innovative, emerging organizations with experienced management teams and our agreement with iMetabolic Biopharma Corporation is another example of such an alliance."
– John Higgins –
CEO at Ligand Pharmaceuticals
Through this raise, we offer communities the opportunity to directly invest in solutions for their own health.
BioTech investment opportunities are typically reserved for an elite circle of the same investors, and we are eager to break this cycle by sharing with you our unique equity crowdfunding campaign.
With major partnerships in place and multiple drug candidates already in development, we are ready to change the way we care for our communities and hope to give loved ones and families as much time together as possible. Invest in iMBP today and become a part of this unique opportunity with us.
iMetabolic Biopharma Corporation (iMBP) is an early-stage drug discovery company innovating at the intersection of technology and biotechnology to develop new, life-saving drugs to fight against some of today's most devastating chronic diseases affecting our loved ones. Currently, we are pre-market, advancing five different disease asset programs, and in the process of developing a proprietary technological platform for the discovery of more effective and less expensive drugs. This will allow us to continuously expand our drug pipeline while increasing company value.
Stephen Adam Munk
Interim - COO and Board Director
David F Hendren
Chief Business Officer
Secretary and General Counsel
Most Recent Fiscal Year-End
Prior Fiscal Year-End
Cash & Cash Equivalents
Revenue & Sales
Costs of Goods Sold
iMetabolic Biopharma Corporation
2155 E Conference Dr STE 115, Tempe, AZ 85284
Minimum Investment Amount
Convertible Promissory Notes
Type of Equity Converted Into
December 31, 2024
Annual Interest Rate
What is a Convertible Note?
A convertible note offers you the right to receive Preferred Stock in iMetabolic Biopharma Corporation. The amount of Preferred Stock you will receive in the future will be determined at the next equity round in which the Company raises at least $5,000,000.00 in a qualified equity financing. The highest conversion price per security is set based on a $25,000,000.00 Valuation Cap or if less, then you will receive a 10.0% discount on the price the new investors are paying. You also receive 3.5% interest per year added to your investment. When the maturity date is reached, if the note has not converted then you are entitled to receive Preferred Stock equal to your investment and interest back at a price per security determined by dividing the Valuation Cap by the aggregate number of outstanding equity securities of the Company as of immediately prior (on a fully diluted basis).
*Annual Interest Rate subject to adjustment based on bonuses below.
Loyalty Bonus | 5% Bonus
As you have previously invested in iMetabolic BioPharma, you are eligible for additional bonus interest.
Invest within the first 72 hours and receive 15% bonus interest.
Invest within the first week and receive 10% bonus interest.
Invest within the first two weeks and receive 5% bonus interest.
$500+ | Knight
Invest $500+ and receive + 5% bonus interest.
$1,000+ | Baron
Invest $1,000+ and receive + 7% bonus interest.
$5,000+ | Duke
Invest $5,000+ and receive + 10% bonus interest + a Membership to the Exclusive iMBP VIP Forum.
$10,000+ | Prince
Invest $10,000+ and receive + 15% bonus interest + a Membership to the Exclusive iMBP VIP Investor Club + complimentary access for you and a guest to a future iMBP sponsored event in Arizona.
$20,000+ | Emperor
Invest $20,000+ and receive + 20% bonus interest + a Membership to the Exclusive iMBP VIP Investor Club + complimentary access for you and a guest to a future iMBP sponsored event in Arizona.
*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonuses from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.
iMetabolic BioPharma will offer 10% additional bonus interest for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
Eligible StartEngine shareholders will receive a 10% increase in the annual interest rate on Convertible Promissory Notes in this Offering. This means your annual interest rate will be 3.85% instead of 3.5%.
This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus and the Loyalty Bonus in addition to the aforementioned bonus.
Irregular Use of Proceeds
The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments. Salary payments made to one’s self, a friend or relative. Any expense labeled “Travel and Entertainment”.
You may think you know what cholesterol is but Dr. Urban A. Kiernan breaks it down even further in today’s Health Tip.
Join Dr. Urban A. Kiernan and iMBP on their mission to improve how drugs are discovered to make them more effective and affordable.
Keep an eye out for more health tips Dr. Urban A. Kiernan!
Due to Regulatory Requirements, iMetabolic Biopharma (iMBP) investors with open or pending investment orders for iMBP require order reconfirmation or the order will be cancelled.
StartEngine will be sending out 3 emails to pending order investors, but reconfirmations need to be completed within 5 business days. Any orders not reconfirmed by March 22nd, 2023 will be cancelled.
Here is a quick message from Dr. Urban A. Kiernan, iMBP Founder and CEO, regarding this and what needs to be done.
Don't wait and keep you order processing. If you have any questions, be please post it in the Discussion Section and will get a response to you as soon as possible.
The iMBP Team
We are excited to have Dr. Jeremy Mills as part of the iMBP technology advisory board and so should you!
Dr. Mill’s research focuses on protein engineering and design using the Rosetta software. Using amino acids not found in nature, Dr. Mills seeks to engineer new proteins that could be used to study biological systems, develop new diagnostic tools, or treat diseases.
Dr. Mills is a native of Houston, Texas and received his undergraduate and graduate degrees at Vanderbilt University and The Scripps Research Institute, respectively.
After postdoctoral studies at the University of Washington, Mills took a position at ASU in 2015. At ASU, he is affiliated with both the School of Molecular Sciences and the Biodesign Center for Molecular Design and Biomimetics.
With his expertise, we are confident he will help shape the way new drugs are discovered! This is your chance to invest in this once in a lifetime opportunity and join and support these highly reputable industry experts!
We are delighted to have the support of an all-star team of experts from not only world renowned institutions such as NYU Langone Health, ASU Biodesign Institute and Howard Hughes Medical Institute, but also from industry giants such as Amazon Web Services (AWS), Ligand Pharmaceuticals (NASDAQ: LGND) and OmniAb (NASDAQ: OABI)!
It shows the dedication and trust they have in us and our mission to develop new, life-saving drugs to fight against some of today's most devastating chronic diseases affecting our loved ones.
We hope you can also show your support and trust in us and our mission.
This is your opportunity to take back control and improve the way drugs are discovered to make them more effective and affordable for millions of people. With a small investment, you could make a positive impact in the biopharma industry!
iMBP is staking its claim in the world of TechBio, helping to bring better and less expensive treatments to you sooner!
iMetabolic Biopharma Corporation (iMBP) files another technology provisional patent application with the United States Patent and Trademark Office (USPTO).
“Software application for graph-based evolution of biologically active molecules”
Filing number: 63/449,455
Inventors: Eric A. Wilson, Ph.D. - Director of Computational Research
Urban A. Kiernan, Ph.D. – Founder and CEO
iMBP is building intellectual property (patents) around computational technology to support its position within the emerging TechBio space. These technologies allow iMBP to continuously improve and expand its drug pipeline in an efficient and cost effective manner.
This interface makes iMBP’s iPlatform™ a more user friendly technology, for improved scientist interaction and improved experimental results.
“This software interface was driven by iMBP’s need to innovate and improve the way things are done. We are a small business and we need to do more with less. This interface helps remove much of the scientific complexity so that someone doesn’t need to have a Ph.D. in computational biology in order to be successful with the iPlatform™.” Dr. Urban A. Kiernan
Join our cause and invest today!
We are excited to be featured on Benzinga, a leading financial news platform that connects the world with news, data and education that makes the path to financial prosperity easier for everyone, everyday.
Being on Benzinga helps highlight iMBP’s mission:
To be the next stage in developing a revolutionary approach to drug discovery, making them more effective and affordable.
Now, everyday investors like you have a chance to invest in iMBP’s innovative approach to drug discovery and the lifesaving treatments it’s aiming to deliver to communities.
Join a community of action and support this early-stage innovation, and own a part of the success!
Please meet Dr. Damon Dixon, a member of the iMBP medical advisory board!
Global Insight Services’ (GIS) latest drug pipeline report lists iMBP as a key player in the hypercholesterol therapeutics space.
Click to watch video - iMBP GIS Report
“It’s a huge honor to be included with multi-billion dollar pharmaceutical companies such as Merck, AstraZeneca, and Amgen.”
- Dr. Urban A. Kiernan -
iMBP Founder, Chairman and CEO
GIS is a leading multi-industry market research firm, committed to providing clients with highest quality data, analysis, and tools to meet all their market research needs.
This report covers detailed insights on hypercholesterolemia drugs under development, assessment by target, mechanism of action, route of administration and molecule type.
We are excited to be included in this report as it validates the work and research we do, and further supports our mission of improving how drugs are discovered, making them more effective and affordable.
You probably know someone who has heart disease, Alzheimer’s Disease, Cardiovascular Disease or type 2 diabetes. What if you had the power to change the way we care for our communities and give hope to loved ones and families with these debilitating illnesses?
With iMBP, you have the power to directly impact how we develop drugs and help find effective solutions to help those affected by these life-changing diseases. You can be part of the solution.
By investing today, you're helping improve the way drugs are discovered. Our technology-powered iPlatform™ removes common roadblocks and barriers, helping make drug development faster, inexpensive, and more cost efficient. With your support, iMBP is the next stage of the biotech evolution.
Change is coming. Be part of the future.
We are thrilled to have Dr. Brent Nannenga, of the Arizona State University BioDesign Institute, as part of the iMBP technology advisory board.
The Dr. Nannenga’s research focuses on using structural biology, specifically crystallography and cryo-EM, to understand and engineer improved biomolecular systems, and to use engineering principles to develop novel methods in structural biology in order to solve high-resolution structures of difficult, yet extremely important targets.
Dr. Nannenga is a native of the Phoenix area and attended ASU as an undergraduate with a degree in chemical engineering. He then moved to the University of Washington where he earned his PhD in chemical engineering.
After graduate school, Dr. Nannenga took on a postdoctoral research position at Janelia Research Campus, part of the Howard Hughes Medical Institute, and following this, he returned to ASU to begin his independent academic career.
In his free time, he enjoys spending time with his family, playing guitar, and enjoying the outdoors.
Members get an extra 10% shares in addition to rewards below!
Earn 10% Bonus Shares
Earn 10% bonus shares in this investment and all eligible investments for an entire year. If you are not already an Owners bonus holder, you can join now, for $275, billed annually.
Invest $500+ and receive + 5% Bonus.
Invest $1,000+ and receive + 7% Bonus.
Invest $5,000+ and receive + 10% Bonus + a Membership to the Exclusive iMBP VIP Forum.
Invest $10,000+ and receive + 15% Bonus + a Membership to the Exclusive iMBP VIP Investor Club + complimentary access for you and a guest to a future iMBP sponsored event in Arizona.
Invest $20,000+ and receive + 20% Bonus + a Membership to the Exclusive iMBP VIP Investor Club + complimentary access for you and a guest to a future iMBP sponsored event in Arizona.
Cancel anytime before 48 hours before a rolling close or the offering end date.
We want you to succeed and get the most out of your money by offering rewards and memberships!
Your info is your info. We take pride in keeping it that way!
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.